Know Cancer

or
forgot password

A Prospective, Double Blind, Randomized, Placebo-Controlled Phase III Trial of Imatinib Re-Challenge in Patients With Gastrointestinal Stromal Tumor Who Had Benefit From Prior Imatinib But Progression From Both Imatinib and Sunitinib


Phase 3
18 Years
N/A
Open (Enrolling)
Both
Gastrointestinal Stromal Tumors

Thank you

Trial Information

A Prospective, Double Blind, Randomized, Placebo-Controlled Phase III Trial of Imatinib Re-Challenge in Patients With Gastrointestinal Stromal Tumor Who Had Benefit From Prior Imatinib But Progression From Both Imatinib and Sunitinib


Inclusion Criteria:



- Patients aged 18 years and older

- Patients with metastatic or unresectable malignant gastrointestinal stromal tumour
which has been histologically confirmed by the detection of CD117 on
immunohistochemical staining or genetically confirmed by the detection of mutation in
KIT or PDGFRα genes on direct sequencing of tumor DNA.

- Prior benefit from 1st line imatinib defined as complete response, partial response,
or stable disease at 6 months after the start of 1st line imatinib

- Patients whose disease has progressed despite at least both prior imatinib therapy
(400mg/day) and then subsequently also failure of prior sunitinib therapy.

- ECOG(Eastern Cooperative Oncology Group) performance status 0 ~ 3

- Adequate bone marrow function as defined by platelets ≥ 75 x 109/L and neutrophils ≥
1.5 x 109/L

- Adequate renal function, with serum creatinine < 1.5 x upper limit of normal

- Adequate hepatic function with serum total bilirubin < 1.5 x upper limit of normal,
alanine aminotransferase or aspartate aminotransferase < 2.5 x upper limit of normal
in the absence of liver metastases, or < 5 x upper limit of normal in the presence of
liver metastases.

- Expected life expectancy of greater than 12 weeks in the absence of any intervention

- No other malignant disease apart from non-melanotic skin cancer or carcinoma in situ
of the uterine cervix or any other cancer except where treated with curative intent >
5 years previously without evidence of relapse

- Written, informed consent to the study

Exclusion Criteria:

- Medical or psychiatric conditions that compromise the patient's ability to give
informed consent or to complete the protocol or a history of non- compliance

- Last dose of radiotherapy received within 4 weeks before the start of study
treatment, excluding palliative radiotherapy

- Obstruction of gastrointestinal tract

- Active gastrointestinal bleeding

- Myocardial infarction within 6 months prior to the study medication, and other
clinically significant heart disease (e.g., unstable angina, congestive heart failure
or uncontrolled hypertension)

- Evidence of severe or uncontrolled systemic disease or any concurrent condition which
in the investigator's opinion makes it undesirable for the patient to participate in
the study or which would jeopardise compliance with the protocol

- Female patients who are pregnant or breast-feeding. Female patients must have had a
negative pregnancy test within one week before starting imatinib.

Type of Study:

Interventional

Study Design:

Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment

Outcome Measure:

Progression-free survival

Outcome Description:

To compare the progression free survival (PFS) assessed by the blinded independent central review following resumption of dosing (re-challenge) with Imatinib plus best supportive care versus placebo plus best supportive care in patients with unresectable or metastatic GIST following failure of at least prior imatinib and sunitinib therapies

Outcome Time Frame:

up tp12 weeks

Safety Issue:

No

Principal Investigator

Yoon-Koo Kang, MD, PhD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Asan Medical Center

Authority:

Korea: Food and Drug Administration

Study ID:

AMC-ONCGI-1001

NCT ID:

NCT01151852

Start Date:

June 2010

Completion Date:

June 2013

Related Keywords:

  • Gastrointestinal Stromal Tumors
  • Imatinib
  • Re-challenge
  • Gastrointestinal Stromal Tumors

Name

Location